Arrowhead reports interim Phase 1/2a data showing ~73% average CSF tau reduction

Arrowhead Pharmaceuticals presented interim results from its Phase 1/2a ARO‑MAPT study in healthy volunteers. The drug lowered cerebrospinal‑fluid total tau by a mean 73% at Day 105, with a maximum individual reduction of 85% and sustained effect 90 days after the last dose. The treatment was generally well tolerated with only mild adverse events reported.

H.C. Wainwright reiterated a Buy rating and a $120 price target, and Cantor Fitzgerald maintained an Overweight rating, citing the strong biomarker data as a catalyst for the stock. The data also validate Arrowhead’s TRiM™ CNS delivery platform, potentially opening pathways to later‑stage studies in tauopathies.

  • 1Mean CSF total tau reduction of 73% at Day 105 in healthy volunteers.
  • 2Maximum individual tau reduction of 85% observed.
  • 3Doses of 2.1 mg/kg, 6.4 mg/kg and 12.8 mg/kg were tested, with the highest dose achieving the 73% mean reduction.
  • 4No serious treatment‑emergent adverse events were reported; most adverse events were Grade 1 or mild.
  • 5H.C. Wainwright reiterated a Buy rating and a $120 price target after the data release.
  • 6Cantor Fitzgerald reiterated an Overweight rating, noting a 70‑75% CSF tau reduction.

Sources